For millions of Americans who have been quietly hoping for a weight-loss solution that doesn’t involve a needle, Wednesday just became a very good day. The U.S. Food and Drug Administration has officially approved Eli Lilly’s much-anticipated weight-loss pill, setting the stage for what promises to be one of the most fiercely competitive pharmaceutical showdowns in recent memory. The rival? Denmark’s Novo Nordisk — the company behind the blockbuster Wegovy — and neither side is backing down.

Meet Foundayo: The Once-a-Day Pill That’s Already Turning Heads

Lilly’s new drug, scientifically known as orforglipron, will be marketed under the brand name Foundayo. It’s a once-daily oral tablet that works by targeting the GLP-1 hormone — the same appetite-suppressing mechanism that made injectable drugs like Ozempic and Wegovy household names. The difference here, of course, is that you swallow it with a glass of water rather than reaching for a syringe.

For people who have shied away from GLP-1 treatments purely because of the injection factor, Foundayo could be the answer they’ve been waiting for.

When Can You Get It — and What Will It Cost?

Lilly has moved quickly to get Foundayo into patients’ hands. The drug will be available for shipping as early as April 6 through the company’s LillyDirect program, with retail pharmacies and telehealth providers following shortly after. For self-pay customers opting for the lowest dose, the monthly price tag sits at $149 — a figure that puts it squarely in line with Novo Nordisk’s competing oral option. It’s an aggressive price point, and clearly a deliberate one.

The Numbers Behind the Pill: How Much Weight Can You Actually Lose?

Clinical trials have painted an encouraging picture. In a rigorous 72-week late-stage trial, participants taking orforglipron shed approximately 12% of their body weight — though for most, the weight loss levelled off toward the end of that period. An earlier 36-week mid-stage trial showed even more striking results, with patients losing close to 15% of their body weight and no obvious plateau in sight.

These are meaningful numbers — not miracle claims, but real, clinically significant reductions that can have a profound impact on a person’s health and quality of life.

Side Effects: What to Know Before You Start

No medication comes without caveats, and Foundayo is no exception. The most commonly reported side effects in trials were gastrointestinal in nature — think nausea and vomiting — and were generally described as mild to moderate. Importantly, Foundayo’s label also carries a boxed warning, the FDA’s most serious cautionary label, flagging an increased risk of thyroid C-cell tumors. It’s worth noting, however, that this is the same warning that appears on Novo Nordisk’s Wegovy — both the oral and injectable versions — so it’s a known consideration across this class of drugs rather than something unique to Lilly’s pill.

Pills vs. Injections: The Bigger Picture

Will Foundayo replace injectable GLP-1 drugs entirely? Probably not — at least not anytime soon. Analysts widely agree that oral options like Foundayo are more likely to carve out their own lane rather than replace injectables altogether. Current projections suggest pills could capture roughly 20% of the weight-loss drug market by 2030, particularly appealing to patients who have a genuine aversion to self-administered shots. It’s a significant slice of a rapidly growing pie.

Lilly itself already dominates the injectable space with tirzepatide — sold as Mounjaro for diabetes and Zepbound for weight loss — which works through a dual mechanism targeting both the GLP-1 and GIP hormones. Foundayo adds a compelling oral option to that already formidable lineup.

How the Trump Administration Helped Speed Things Along

The approval didn’t happen in a vacuum. Foundayo was granted a voucher under the Commissioner’s National Priority Voucher Program — an initiative designed to fast-track FDA decisions for drugs deemed to have critical public health or national security significance. Lilly received this voucher as part of a broader agreement with the Trump administration, under which the company committed to lowering the prices of its weight-loss medicines for government programs and cash-paying patients.

FDA Commissioner Marty Makary was quick to address any concerns about corners being cut, telling reporters that the review process for Foundayo was just as thorough as the traditional, longer pathway would have been. In other words — fast doesn’t mean rushed.

Markets React: Lilly Up, Novo Down

Wall Street wasted no time responding. Lilly shares climbed nearly 5% following the approval announcement, while U.S.-listed shares of Novo Nordisk slipped by close to 2%. It’s a clear signal that investors see Foundayo as a genuine threat to Novo’s dominance in the GLP-1 space — and that the competition between these two pharmaceutical titans is only just heating up.

The weight-loss drug wars have a new front line. And this time, it fits in the palm of your hand.